法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 奥锐特药业股份有限公司 2022 年限制性股票激励计划 第三个解除限售期解除限售、调整回购价格 及回购注销相关事项 的法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 GrandallBuilding,No.2＆No.15,BlockB,BaitaPark,OldFuxingRoad,Hangzhou,Zhejiang310008,China 电话/Tel：（+86）（571）85775888 传真/Fax：（+86）（571）85775643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年十月 法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 奥锐特药业股份有限公司 2022 年限制性股票激励计划 第三个解除限售期解除限售、调整回购价格及回购注 销相关事项 的法律意见书 致：奥锐特药业股份有限公司 根据奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）与 ...

奥锐特药业股份有限公司 2025 年第三季度报告 证券代码：605116 证券简称：奥锐特 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 415,085,513.31 ...

奥锐特药业股份有限公司章程 二○二五年九月 | | | 奥锐特药业股份有限公司 公司章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行 为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国 证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下简 称"公司"）。 公司由奥锐特药业有限公司依法变更发起设立，奥锐特药业有限公司的原有各 投资者即为公司发起人；公司在浙江省市场监督管理局注册登记，取得营业执照， 统一社会信用代码：9133100070471006XJ。 第三条 公司于 2020 年 9 月 21 日经中国证券监督管理委员会（以下简称"中 国证监会"）核准，首次向社会公众公开发行人民币普通股 4,100 万股，在上海证 券交易所上市。 第四条 公司名称：奥锐特药业股份有限公司 英文名称：Aurisco Pharmaceutical Co., Ltd 第五条 公司住所：浙江省天台县八都工业园区；邮政编码：317200。 第六条 公司注册资本为人民币 406,195,234 元。 ...

Core Insights - The stock price of Aorite has decreased by 2.15% on October 13, trading at 22.31 CNY per share with a market capitalization of 9.062 billion CNY [1] - Aorite's stock has increased by 7.10% year-to-date, with a slight decline of 0.09% over the last five trading days and a 3.55% drop over the last 20 days [2] Company Overview - Aorite Pharmaceutical Co., Ltd. is located in Tiantai County, Zhejiang Province, established on March 5, 1998, and listed on September 21, 2020 [2] - The company's main business involves the research, production, and sales of specialty raw materials and pharmaceutical intermediates, with revenue composition as follows: 85.12% from raw materials and intermediates, 11.64% from finished drugs, 2.74% from import and export trade, and 0.50% from other sources [2] - Aorite belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and raw material drug sector, with concepts including pharmaceutical e-commerce, assisted reproduction, raw materials, peptide drugs, and synthetic biology [2] Financial Performance - For the first half of 2025, Aorite achieved operating revenue of 822 million CNY, representing a year-on-year growth of 12.50%, and a net profit attributable to shareholders of 235 million CNY, up 24.55% year-on-year [2] - The company has distributed a total of 372 million CNY in dividends since its A-share listing, with 272 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, Aorite had 11,800 shareholders, an increase of 7.86% from the previous period, with an average of 33,770 circulating shares per shareholder, a decrease of 7.29% [2]

格隆汇10月9日丨奥锐特(605116.SH)公布，截至2025年9月30日，公司通过上海证券交易所交易系统以 集中竞价交易方式已累计回购公司股份174.67万股，占公司目前总股本的比例为0.43%，回购成交的最 高价为22.59元/股，最低价为18.83元/股，支付的资金总额为人民币3560.75万元（不含交易费用）。 ...

Group 1 - Company Aorite (SH 605116) announced a share buyback of approximately 1.75 million shares, representing 0.43% of its total share capital, with a total expenditure of about 35.61 million RMB [1] - The highest buyback price was 22.59 RMB per share, while the lowest was 18.83 RMB per share [1] - For the first half of 2025, Aorite's revenue composition was as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trading, and 0.5% from other businesses [1] Group 2 - Aorite's market capitalization is currently 9.2 billion RMB [2]

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 2025 年 1 月 21 日，奥锐特药业股份有限公司（以下简称"公司"）召开第三 届董事会第十二次会议，会议以 9 票同意、0 票反对、0 票弃权审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞价交易方式回 购公司股份，回购的股份全部用于转换公司可转债。本次回购股份的资金总额为 不低于人民币 6,000 万元（含），不高于人民币 12,000 万元（含），回购价格不超 过人民币 25.00 元/股（含），回购期限自公司董事会审议通过回购方案之日起不 超过 12 个月。 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《奥锐 特药业股份有限公司关于以集中竞价交易方式回购股份方案的公告》（公告编号： 2025-005）、《奥锐特药业股份有限公司关于以集中竞价交易方式回购股份的回购 报告书》（公告编号：2025-007）。 2025 年 5 月 16 ...

关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 9 月 30 日，累计已有面值 8,000 元"奥锐 转债"转为公司 A 股普通股，累计转股股数为 313 股，占"奥锐转债"转股前 公司已发行普通股股份总额的 0.0001%。 未转股可转债情况：截至 2025 年 9 月 30 日，尚未转股的"奥锐转债" 面值为人民币 812,112,000 元，占"奥锐转债"发行总量的比例为 99.9990%。 证券代码：605116 证券简称：奥锐特 公告编号：2025-074 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 本季度转股情况："奥锐转债"自 2025 年 2 月 5 日起可转换为公司股票， 2025 年 7 月 1 日至 2025 年 9 月 30 日期间无转股。 一、可转债发行上市概况 （一）可转债发行情况 经中国证券监督管理委员会《关于同意奥锐特药业股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔 ...

Core Viewpoint - The board of Aurite Pharmaceutical Co., Ltd. has approved a share repurchase plan to buy back shares through centralized bidding, with a budget of 60 million to 120 million yuan for the purpose of converting the company's convertible bonds [1] Summary by Relevant Sections - **Repurchase Plan Details** - The repurchase amount is set between 60 million and 120 million yuan, with a repurchase period of 12 months [1] - The upper limit for the repurchase price was originally not to exceed 25 yuan per share, adjusted to not exceed 24.71 yuan per share after equity distribution [1] - **Current Repurchase Status** - As of September 30, the company has repurchased a total of 1,746,738 shares, accounting for 0.43% of the total share capital [1] - The total funds paid for the repurchase amount to 35,607,509.68 yuan, with a repurchase price range between 18.83 and 22.59 yuan per share [1]

Report Summary - The report presents the top ten convertible bonds for October 2025, along with an analysis of the issuing companies, including their business profiles, financial performance, and key attractions [13][23][35] Top Ten Convertible Bonds in October 2025 1. Zhongte Convertible Bond - Rating: AAA; 9 - month - end closing price: 112.896 yuan; Conversion premium rate: 85.92%; PE - TTM of the underlying stock: 13.22 [7][13] - Company: A globally leading specialized special - steel material manufacturer with a production capacity of about 20 million tons of special - steel materials per year. It has multiple production and raw - material bases, forming a strategic layout along the coast and rivers [13] - Financials: In 2024, revenue was 109.203 billion yuan (YoY - 4.22%), net profit attributable to shareholders was 5.126 billion yuan (YoY - 10.41%). In H1 2025, revenue was 54.715 billion yuan (YoY - 4.02%), net profit attributable to shareholders was 2.798 billion yuan (YoY + 2.67%) [13] - Key attractions: It is one of the world's most comprehensive special - steel enterprises in terms of variety and specification, with leading cost - control ability and potential for external expansion [14] 2. Shanlu Convertible Bond - Rating: AAA; 9 - month - end closing price: 119.346 yuan; Conversion premium rate: 48.74%; PE - TTM of the underlying stock: 4.08 [7][23] - Company: Mainly engaged in road and bridge construction and maintenance, and also expanding into other fields. It can provide one - stop comprehensive services [23] - Financials: In 2024, revenue was 71.348 billion yuan (YoY - 2.3%), net profit attributable to shareholders was 2.322 billion yuan (YoY + 1.47%). In H1 2025, revenue was 28.575 billion yuan (YoY + 0.26%), net profit attributable to shareholders was 1.029 billion yuan (YoY + 0.89%) [23] - Key attractions: It has the concept of "China - specific valuation", potential for improvement in various aspects under the debt - resolution background, and opportunities from regional infrastructure construction and the Belt and Road Initiative [24] 3. Hebang Convertible Bond - Rating: AA; 9 - month - end closing price: 126.41 yuan; Conversion premium rate: 21.55%; PE - TTM of the underlying stock: - 168.47 [7][35] - Company: With advantages in mineral resources and gas supply, it has completed a basic layout in the chemical, agricultural, and photovoltaic fields [35] - Financials: In 2024, revenue was 8.547 billion yuan (YoY - 3.13%), net profit attributable to shareholders was 31 million yuan (YoY - 97.55%). In H1 2025, revenue was 3.921 billion yuan (YoY - 19.13%), net profit attributable to shareholders was 52 million yuan (YoY - 73.07%) [35] - Key attractions: Its phosphate mines and salt mines have good profit - making potential, and the liquid methionine business is a major profit contributor [36] 4. Aima Convertible Bond - Rating: AA; 9 - month - end closing price: 128.513 yuan; Conversion premium rate: 38.62%; PE - TTM of the underlying stock: 13.41 [7][45] - Company: The leading enterprise in the electric two - wheeled vehicle industry, mainly engaged in R & D, production, and sales of electric two - wheeled vehicles [45] - Financials: In 2024, revenue was 21.606 billion yuan (YoY + 2.71%), net profit attributable to shareholders was 1.988 billion yuan (YoY + 5.68%). In H1 2025, revenue was 13.031 billion yuan (YoY + 23.04%), net profit attributable to shareholders was 1.213 billion yuan (YoY + 27.56%) [45] - Key attractions: It may benefit from government subsidies, new national standards, and potential improvement in gross margin [46] 5. Xingye Convertible Bond - Rating: AAA; 9 - month - end closing price: 120.859 yuan; Conversion premium rate: 29.02%; PE - TTM of the underlying stock: 5.43 [7][54] - Company: One of the first joint - stock commercial banks in China, evolving into a modern financial service group [54] - Financials: In 2024, revenue was 212.226 billion yuan (YoY + 0.66%), net profit attributable to shareholders was 77.205 billion yuan (YoY + 0.12%). In H1 2025, revenue was 110.458 billion yuan (YoY - 2.29%), net profit attributable to shareholders was 43.141 billion yuan (YoY + 0.21%) [54] - Key attractions: It has stable asset quality and scale growth [55] 6. Wentai Convertible Bond - Rating: AA -; 9 - month - end closing price: 128.918 yuan; Conversion premium rate: 20.93%; PE - TTM of the underlying stock: - 23.14 [7][66] - Company: A globally leading semiconductor enterprise adopting the IDM model, providing R & D, manufacturing, and testing services [66] - Financials: In 2024, revenue was 73.598 billion yuan (YoY + 20.23%), net profit attributable to shareholders was - 2.833 billion yuan (YoY - 339.83%). In H1 2025, revenue was 25.341 billion yuan (YoY - 24.56%), net profit attributable to shareholders was 474 million yuan (YoY + 237.36%) [66] - Key attractions: After focusing on the semiconductor business, it benefits from market recovery and has growth potential in the automotive and consumer electronics fields [67] 7. Chongyin Convertible Bond - Rating: AAA; 9 - month - end closing price: 121.778 yuan; Conversion premium rate: 31.87%; PE - TTM of the underlying stock: 5.88 [7][77] - Company: An early local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, with a wide range of business scopes [77] - Financials: In 2024, revenue was 13.679 billion yuan (YoY + 3.54%), net profit attributable to shareholders was 5.117 billion yuan (YoY + 3.8%). In H1 2025, revenue was 7.659 billion yuan (YoY + 7%), net profit attributable to shareholders was 3.19 billion yuan (YoY + 5.39%) [77] - Key attractions: It can benefit from the development of the Chengdu - Chongqing economic circle, has stable asset - scale growth, and effective risk - control strategies [78] 8. Tianye Convertible Bond - Rating: AA +; 9 - month - end closing price: 120.562 yuan; Conversion premium rate: 48.06%; PE - TTM of the underlying stock: 146.42 [7][89] - Company: A leading enterprise in the chlor - alkali chemical industry in Xinjiang, with an integrated circular economy industrial chain [89] - Financials: In 2024, revenue was 11.156 billion yuan (YoY - 2.7%), net profit attributable to shareholders was 68 million yuan (YoY + 108.83%). In H1 2025, revenue was 5.16 billion yuan (YoY - 0.98%), net profit attributable to shareholders was - 9 million yuan (YoY - 228.22%) [89] - Key attractions: It may benefit from the price change of caustic soda and has plans for dividend increase and coal - mine projects [90] 9. Aorui Convertible Bond - Rating: AA -; 9 - month - end closing price: 126.412 yuan; Conversion premium rate: 40.56%; PE - TTM of the underlying stock: 22.72 [7][100] - Company: A company focusing on the R & D, production, and sales of complex APIs and preparations, with leading positions in multiple fields [100] - Financials: In 2024, revenue was 1.476 billion yuan (YoY + 16.89%), net profit attributable to shareholders was 355 million yuan (YoY + 22.59%). In H1 2025, revenue was 822 million yuan (YoY + 12.5%), net profit attributable to shareholders was 235 million yuan (YoY + 24.55%) [100] - Key attractions: It has a growing dealer network, expanding preparation products, and high - quality customer resources [101] 10. Yushui Convertible Bond - Rating: AAA; 9 - month - end closing price: 125.081 yuan; Conversion premium rate: 30.74%; PE - TTM of the underlying stock: 26.93 [7][108] - Company: The largest integrated water supply and drainage enterprise in Chongqing, with a stable monopoly position [108] - Financials: In 2024, revenue was 6.999 billion yuan (YoY - 3.52%), net profit attributable to shareholders was 785 million yuan (YoY - 27.88%). In H1 2025, revenue was 3.519 billion yuan (YoY + 7.16%), net profit attributable to shareholders was 458 million yuan (YoY + 10.06%) [108] - Key attractions: It has a high market share, is expanding business externally, and has effective cost - control measures [109]